카바지탁셀

한글명:카바지탁셀

카스 번호183133-96-2

상품명:Cabazitaxel

CBNumberCB42517227

분자식C45H57NO14

포뮬러 무게835.93

MOL 파일183133-96-2.mol

동의어(한글)

카바지탁셀

화학적 성질

녹는점	180 °C
끓는 점	870.7±65.0 °C(Predicted)
밀도	1.31
저장 조건	Inert atmosphere,Store in freezer, under -20°C
용해도	클로로포름(약간 용해됨), DMSO(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태	백색 고체.
산도 계수 (pKa)	11.20±0.46(Predicted)
색상	흰색에서 황백색까지
InChIKey	BMQGVNUXMIRLCK-JACFBOAKNA-N

위험 및 안전 성명

안전지침서

24/25

HS 번호

29329990

NFPA 704:

	0
2		0

그림문자(GHS)

카바지탁셀 화학적 특성, 용도, 생산

개요
In June 2010, the U.S. FDA approved cabazitaxel (also referred to as XRP6258 and RPR 116258A) in combination with the steroid prednisone for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC) for patients who were previously treated with a docetaxelcontaining regimen for late-stage disease.
Cabazitaxel is a semisynthetic analog of the natural product taxol, which is isolated from the bark of the yew tree. Cabazitaxel is a microtubule inhibitor that binds to the taxol-binding site of tubulin. Similar to other tubulin inhibitors of the taxol class, cabazitaxel inhibits microtubule disassembly resulting in mitotic blockade and cell death. Docetaxel, also a semisynthetic taxol analog, was approved by the FDA for the treatment of mCRPC in 2004. However, docetaxel is a substrate for P-gp, which is thought to contribute to the constitutive and acquired resistance of cancer cells to taxanes. Cabazitaxel has poor affinity for P-gp and showed antitumor activity in preclinical in vitro studies and in vivo tumor models that overexpress this protein. Cabazitaxel is synthesized on a commercial scale from 10-deacetylbaccatin .
화학적 성질
White solid
용도
Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid.
정의
ChEBI: A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hy roxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.
Clinical Use
Cabazitaxel was developed by Sanofi-Aventis as an intravenous injectable drug for the treatment of hormone-refractory metastatic prostate cancer. As a microtubule inhibitor, cabazitaxel differs from docetaxel because it exhibits a much weaker affinity for P-glycoprotein (P-gp), an adenosine triphosphate (ATP)-dependent drug efflux pump. Cancer cells that express P-gp become resistant to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp. Clinical studies confirmed that cabazitaxel retains activity in docetaxel-resistant tumors. Common adverse events with cabazitaxel include diarrhea and neutropenia. Cabazitaxel in combination with prednisone is an important new treatment option for men with docetaxel-refractory metastatic CRPC (castration-resistant prostate cancer).

카바지탁셀 준비 용품 및 원자재

카바지탁셀 공급 업체

카바지탁셀 관련 검색

Send Inquriy